Lifecore Biomedical, Inc. (LFCR): Cash & Equivalents
$8.27M
As of 2025-05-25
$17.24M
As of 2026-06-30
+102.8%
3-year compound annual growth
+87.1%
5-year compound annual growth
-5.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-05-25 | $8.27M | -2.3% | 2025-08-07, Balance as of period end |
| 2024-05-26 | $8.46M | -55.7% | 2025-08-07, Balance as of period end |
| 2023-05-28 | $19.09M | n/a | 2024-08-26, Balance as of period end |
| 2023-02-26 | $2.95M | n/a | 2024-03-20, Balance as of period end |
| 2022-11-27 | $5.94M | n/a | 2024-03-20, Balance as of period end |
| 2022-08-28 | $2.54M | n/a | 2024-03-20, Balance as of period end |
| 2022-05-29 | $991.0K | n/a | 2024-03-20, Balance as of period end |
| 2022-02-27 | $1.10M | n/a | 2024-03-20, Balance as of period end |
| 2021-11-28 | $609.0K | n/a | 2024-03-20, Balance as of period end |
| 2021-08-29 | $939.0K | n/a | 2024-03-20, Balance as of period end |
| 2021-05-30 | $763.0K | n/a | 2024-03-20, Balance as of period end |
| 2021-02-28 | $1.85M | n/a | 2024-03-20, Balance as of period end |
| 2020-11-29 | $2.48M | n/a | 2024-03-20, Balance as of period end |
| 2020-08-30 | $439.0K | n/a | 2024-03-20, Balance as of period end |
| 2020-05-31 | $360.0K | -66.7% | 2023-03-16, Balance as of period end |
| 2019-05-26 | $1.08M | -62.7% | 2021-07-29, Balance as of period end |
| 2018-05-27 | $2.90M | -51.7% | 2020-08-14, Balance as of period end |
| 2017-05-28 | $6.00M | -39.8% | 2019-08-01, Balance as of period end |
| 2016-05-29 | $9.97M | -29.4% | 2018-08-09, Balance as of period end |
| 2015-05-31 | $14.13M | -0.8% | 2018-03-15, Balance as of period end |
| 2014-05-25 | $14.24M | +3.8% | 2016-08-01, Balance as of period end |
| 2013-05-26 | $13.72M | -38.1% | 2015-07-31, Balance as of period end |
| 2012-05-27 | $22.18M | +172.6% | 2014-08-01, Balance as of period end |
| 2011-05-29 | $8.13M | -70.8% | 2013-08-07, Balance as of period end |
| 2010-05-30 | $27.82M | n/a | 2012-08-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.27M | -2.3% |
| Xencor Inc (XNCR) | 2025-12-31 | $54.07M | +32.3% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $37.07M | +213.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $60.54M | -3.1% |
| Elite Pharmaceuticals Inc (ELTP) | 2024-03-31 | $7.11M | -9.3% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $57.22M | -68.7% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $167.81M | +344.0% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $28.65M | +11.0% |
Compare LFCR, XNCR, GYRE, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗